United StatesBreaking News

Apple (NASDAQ:AAPL) reclaimed the title of the world’s most valuable public company on Monday as its market capitalisation reached about $4.94 trillion after shares rose more than 1%.

Kate Moore, Citi Wealth chief investment officer, says she's not worried about a recession in the US, but she says a pause in capex spending could "be another shock to sentiment." She speaks on "Bloomberg Open Interest."

Yardeni Research President Edward Yardeni discusses inflation concerns, market optimism, a strong earnings season and personal retirement planning. He speaks with Tom Keene and Scarlet Fu on 'Bloomberg Money.'

On this episode of Stock Movers: - Forte Bioscience (FBRX) is soaring as Argenx SE agreed to buy Forte Biosciences Inc. for about $2.2 billion in cash to expand its portfolio of immunology medicines. - Astrazeneca (AZN) shares rose after it reported higher-than-expected profit, buoyed by blockbuster cancer medicines, with earnings per share rising 21% to $2.63 last quarter. - Paramount Skydance (PSKY) shares are reacting to news that it paused its blockbuster deal for Warner Bros.

SpaceX (NASDAQ:SPCX) shares fell to a new all-time low of $109.53 on Monday despite the company completing a successful Starship test flight days earlier.

Oil prices declined and U.S. stocks gained on Monday after a pause in fighting between the United States and Iran increased expectations that diplomatic efforts could continue.

MapLight Therapeutics NASDAQ:MPLT) reported positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA in adults with acute exacerbation of schizophrenia.

Neumora Therapeutics (NASDAQ:NMRA) reported favorable results from a repeat 162-animal toxicology study for its NMRA-215 obesity program.

A pause in attacks for a third straight day between the US and Iran helped to push down oil prices and boost global stock and bond markets following two weeks of clashes. Tyler Kendall reports on Bloomberg Television.

VERAXA Biotech (NASDAQ:VRXA) announced that its VXA-222 bispecific antibody-drug conjugate programme has reached a technical milestone and advanced into the next phase of its collaboration with OmniAb (NASDAQ:OABI).

Yarrow Bioscience (NASDAQ:YARW) completed its merger with VYNE Therapeutics and closed previously announced private financings totaling approximately $200 million to support its biotechnology development programme.

Lakeland Financial Corporation (NASDAQ:LKFN) reported record second-quarter 2026 net income of $28.4 million, or $1.13 per diluted share, compared with $27 million, or $1.04 per share, in the second quarter of 2025.